01
Biopharma investments are up, led by large mezz deals
IPO valuations and proceeds are on record pace and post-IPO stock performance has been incredible.
02
Dx/Tools are on track for record investment, four IPOs boasted $1B+ market caps at mid-year
Led by many companies leveraging their technologies to aid the COVID-19 response.
03
HealthTech led post-IPO performance with a $2B+ IPO that then increased its stock price by over 100%
Companies focused on providing alternative care outside the hospital raised 46% of capital in this sector.
A flurry of venture fundraising in 1H 2020 nearly eclipsed 2019’s full-year record, $10.7B $10.4B building on a three-year trend of increased allocation to healthcare.
The first half of 2020 produced the largest two-quarter investment total ever for venture-backed healthcare companies, despite financial market turbulence and setbacks to company product development, clinical trials, and revenues caused by COVID-19.
Many venture investors have a bifurcated early-stage strategy, balancing internally-fashioned large Series A deals while supporting company creation and/or founder-led early-stage science.
HealthTech Series A investments rose 40% and total funding increased by 20%, driven by deals in the alternative care, wellness & education, and clinical trial enablement (CTE) subsectors.
R&D Tools deals represented almost half of all Series A deal activity (48%). A number of these companies, are leveraging their technologies to aid the COVID-19 response.
Explore other Healthcare reports
Written and researched by SVB experts
Our deep relationships with top life science and healthcare entrepreneurs and investors inform our insights and give us a vantage point unlike any other bank.
Stay up to date with SVB
Get our healthcare insights in your inbox